This morning, Pulmatrix announced it received European patent for its inhaled drug delivery technology. The biotech stock soared 39% to close at $3.88 per share on 22.8 million shares traded. Today marks the second time in March Pulmatrix has been awarded the Daily Stock Challenge Breakout award.

We notified investors on March 17th after Pulmatrix’s stock gapped up 32%. In Pulmatrix Moves Higher One Week After Financials, we wrote,

“Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The company is utilizing it’s patented iSPERSE™ technology.

Pulmatrix has had a huge 2017, rising from below $1 per share to a high of $6.98.

The Company’s proprietary product pipeline is working to advance treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). Approximately 30,000 people in the United States have cystic fibrosis.”

Click here to read the entire story.

Pulmatrix traded between $2.32 and $3.77 per share March 17th. After a weak start to the month, Pulmatrix is rebounding with a vengeance.


Pulmatrix – 1 Month Chart

Pulmatrix Stock Chart


Pulmatrix’s Stock responds latest European Union Patent


Pulmatrix announced this morning that it had received a key patent from the European Union.

Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix, commented,

“This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery.”

The company reported,

“The new EU patent (EP 2410981 B1) follows on similar patents that Pulmatrix has been granted in the United States and Japan. The most important of those patents is US 9,433,576, which gives broad protection to Pulmatrix’s innovative drug delivery technology—and to its use to treat a wide variety of diseases.”

Dr. Clarke added,

“This new patent means that we are now protected from competitors copying our advances in Europe, as well as in the United States.”

Click here to read the entire press release.

Pulmatrix pushes ‘Readski’ and ‘joeyg48’ higher in March Stock Challenge


New member ‘Readski’s one-day return was 22.06% Tuesday. Past Stock Challenge Champ and long-time member ‘joeyg48’ also selected Pulmatrix for March and saw his return jump 19.10% Tuesday.

Everyone is chasing ‘screefer’ and his 233.57% return. With just days left in March’s Stock Challenge it looks as if he may finally win the silver bullion and prize package.

View Top 20 Leader Board